TITLE

Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial

AUTHOR(S)
Sideras, Kostandinos; Schaefer, Paul L.; Okuno, Scott H.; Sloan, Jeff A.; Kutteh, Leila; Fitch, Tom R.; Dakhil, Shaker R.; Levitt, Ralph; Alberts, Steven R.; Morton, Roscoe F.; Rowland, Kendrith M.; Novotny, Paul J.; Loprinzi, Charles L.
PUB. DATE
June 2006
SOURCE
Mayo Clinic Proceedings;Jun2006, Vol. 81 Issue 6, p758
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer. PATIENTS AND METHODS: Between December 1998 and June 2001, we performed a randomized controlled study of patients with advanced cancer. Initially, the study was double blinded and placebo controlled, with the patients receiving daily injections of 5000 U of LMWH or saline. However, because of low accrual midway through the study, the placebo injection arm was eliminated, and the study became open labeled, with patients receiving either LMWH injections plus standard clinical care or standard clinical care alone. The primary study end point was overall survival. RESULTS: Of 141 patients randomized to this clinical trial, 3 dropped out, leaving 138 patients. The median survival time was 10.5 months (95% confidence Interval, 7.6-12.2 months) for the combined standard care and placebo groups. The median survival time for the combined LMWH arms was 7.3 months (95% confidence Interval, 4.8-12.2 months). These median survival times were not significantly different (log-rank P = .46). The median survival times for the blinded and unblinded LMWH groups were 6.2 months and 9.0 months, respectively. The median survival times were 10.3 months for the blinded placebo arm and 10.5 months for the standard care arm. The rate of severe or life-threatening venous thromboembolism was 6% in the LMWH arms and 7% in the control arms. The rate of severe or life-threatening bleeding was 3% in the LMWH arms and 7% in the control arms. CONCLUSION: This trial was unable to demonstrate any survival benefit for LMWH In patients with advanced cancer.
ACCESSION #
21258758

 

Related Articles

  • Hospitals Focus on Cancer Clinical trials, cancer centers help patients receive state-of-the-art care in Alaska. West, Gail // Alaska Business Monthly;Mar2009, Vol. 25 Issue 3, p50 

    The article focuses on the significance of clinical trials and cancer centers for cancer patients in Alaska. It mentions that other hospitals in the state such as the Alaska Regional and Fairbanks Memorial also participate in clinical trials. It notes that cancer clinical trials do not provide...

  • Response: Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer. Fojo, Tito; Amiri-Kordestani, Laleh; Bates, Susan E. // JNCI: Journal of the National Cancer Institute;May2012, Vol. 104 Issue 9, p718 

    The authors respond to the comments made on their article "Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer." They appreciate the discusser for his concern with the trend in randomized clinical trials in oncology that allows patient access to experimental...

  • Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective. VanHoff, David; Hesser, Tanya; Kelly, Katherine Patterson; Freyer, David; Stork, Susan; Sung, Lillian // BMC Medical Research Methodology;2013, Vol. 13 Issue 1, p1 

    Background Accrual to Cancer Control and Supportive Care (CCL) studies can be challenging. Our objective was to identify facilitators and perceived barriers to successful Children's Oncology Group (COG) CCL accrual from the clinical research associate (CRA) perspective. Methods A survey was...

  • The Emotional Toll of Reporting on a Cancer Trial. Laidman, Jenni // Nieman Reports;Summer2003, Vol. 57 Issue 2, p36 

    Presents an article on making stories about cancer. Efforts to make cancer as the main topic of medical reporting; Health condition of cancer patient Pat Krzeminski; Clinical trials for the molecule H11.

  • Clinical Trial Results Applied to Management of the Individual Cancer Patient. Jatoi, Ismail; Proschan, Michael A. // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1184 

    The application of clinical trial results to the management of the individual cancer patient is not always straightforward. The results of a clinical trial indicate the “average” effect of an intervention, often expressed in terms of an absolute risk reduction, which is an estimate...

  • Developing core sets for patients with head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF). Tschiesner, U.; Cieza, A.; Rogers, S. N.; Piccirillo, J.; Funk, G.; Stucki, G.; Berghaus, A. // European Archives of Oto-Rhino-Laryngology;Oct2007, Vol. 264 Issue 10, p1215 

    Problems in functioning are frequently seen in survivors of head and neck cancer (HNC) and proof to have increasing impact on their quality of life. With the approval of the International Classification of Functioning, Disability and Health (ICF) by the World Health Assembly in May 2001, we can...

  • Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. Murthy, Vivek H.; Krumholz, Harlan M.; Gross, Cary P. // JAMA: Journal of the American Medical Association;6/9/2004, Vol. 291 Issue 22, p2720 

    Context Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective To characterize the representation of racial and ethnic minorities, the...

  • Cancer Detection Drug Enters Phase III Clinical Trial. N. O. // Access;Mar2006, Vol. 20 Issue 3, p49 

    The article reports that pharmaceutical form Zila Inc. has started its phase III clinical trial for OraTest, the oral cancer detection drug manufactured in the company. The trial requires over 4,000 high-risk patients who are readily available. It is estimated to last a year.

  • Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Crott, Ralph; Briggs, Andrew // European Journal of Health Economics;Aug2010, Vol. 11 Issue 4, p427 

    Although cancer-specific Health-Related Quality of Life (HRQOL) are commonly included in randomized clinical trials or other prospective non-randomized clinical studies, it is rare that preference-based instruments are used that allow the calculation of a utility weight suitable for estimating...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics